INTRODUCTION
Before the 1970s, scientists used Serratia marcescens (S. marcescens) as an easily detected biomarker because of its distinctive red pigmentation. It was regularly sprayed on the hands and lips of test subjects, aerosolized in hospital ventilation systems and used as a biomarker in blood [1] . From 1949 to 1968, US Army and Navy experiments in San Francisco aerosolized the bacteria to study the behavior/viability of biologic weapons over large geographic areas; within days, the bacteria was detected 80 meters inland. Shortly after experiments in September 1950 [2, 3] , local concerns arose when Wheat et al. [4] reported 11 patients who developed S. marcescens urinary tract infections after cystoscopy or prostatectomy. Classified government documents regarding the aerosolization experiments were publically released after the death of one of the patients in Wheat's report who developed bactermia.
S. marcescens affected immunocompromised residents of San Francisco repeatedly in the 1960s and 1970s. Nineteen cases of S. marcescens endocarditis and one case of S. marcescens vertebral osteomyelitis were reported in intravenous drug users [5, 6] . Authors of these reports suggested that the government experi- Today, S. marcescens as a virulent agent in nosocomial infections; it thrives in moist environments and spreads through water droplets and contact. Breast cancer patients who undergo chemotherapy and radiation are a unique, immunocompromised group and we investigate the risks of S. marcescens in those who received tissue expander-based reconstruction. This paper reviews a series of cases with cultures positive for S. marcescens and identifies risk factors, including geographic, for pathogenic sequelae of S. marcescens.
Methods
Between 2007 and 2011, 142 women underwent mastectomy for breast cancer and had immediate subpectoral tissue expander placement with or without acellular dermal matrix (ADM) by the senior author. After the desired tissue expander size was obtained using weekly saline injections, (one to four months after placement), implant reconstruction was done using silicone prostheses. The senior author routinely takes breast capsule cultures at the time of tissue expander exchange or explant. Patient demographics, cancer treatment and surgical details were recorded. Inclusion criteria for this study were all patients who received immediate tissue expander-based reconstruction for mastectomy, with subsequent implant exchange. Descriptive statistics of patient demographics, culture results and surgical complications were performed using Stata (ver. 11.0, StataCorp LP, College Station, TX, USA).
CASE
Twenty-three of 142 women had positive breast capsule cultures, including Enterococcus, S. marcescens, Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus (MRSA), Proteus mirabilis and E. coli. 11 of the 23 culture positive patients had ADM with tissue expander placement. The first patient, age 31, had had received bilateral immediate tissue expander placement after bilateral modified radical mastectomies. She had a 16 week course of chemotherapy that started one month postoperatively when all incisions were well healed and expansion began. At three months postoperatively, she had transient chemotherapy-induced neutropenia when her white blood cell count (WBC) dropped to 2.5; at that time, 400 mL of expansion had been completed in each breast. One week after the neutropenic episode, clinical infection in the right breast emerged, and her tissue expander required explantation. Six months after initial tissue expander placement, clinical infection occurred in the left breast, requiring explantation. Cultures at the time of explantation bilaterally grew S. marcescens. Fig. 1 , the left breast at the time of explantation, highlights the orangered pigmentation characteristic of S. marcescens. The second patient, age 44, had bilateral mastectomies with immediate tissue expander placement and silicone breast implant exchange 6 months later. With chemotherapy, she had both transient neutropenia (WBC, 3.5) and leukocytosis (WBC > 36) during her expansion period. One month after silicone implant exchange, the left breast developed clinical infection requiring explantation with operative cultures that grew S. marcescens. Both patients healed well after explantation.
Of the 23 culture positive patients, no others required explantation. Five had clinical cellulitis that responded to antibiotic therapy; these patients were culture positive with Enterococcus, Pseudomonas, MRSA, Staphlococcus, E. Coli and Propionibacterium. Two patients required surgical debridement; both of these patients had ADM tissue expander reconstruction and chemotherapy. All patients all radiation and chemotherapy had been completed after tissue expander placement but before implant exchange.
DISCUSSION
Our records of implant-based breast reconstruction are uniquely complete because breast capsule cultures were taken for all patients at the time of implant exchange (or explantation, when applicable), regardless of the patient's clinical status. Thus, we were able to highlight common contaminants, as well as bacteria that may become clinically pathologic.
Whether the water in San Francisco is currently colonized by S. marcescens is unknown, as no follow-up studies or reports quantify the burden of S. marcescens on public waters and land. Several studies have reported that bodies of water, soil, produce, and insects are natural carriers of S. marcescens. Therefore, it is possible that San Franciscans are at higher risk for colonization given the history of military contamination. Though S. marcescens was released into the water over 40 years ago, the bacteria's ability to thrive in moist environments and a wide temperature range may have potentiated its survival to the present day. While S. marcescens optimally grows at 37 degrees Celsius, it can grow in a temperature range from 5 to 40 degrees Celsius [7] . Both patients in this report have had extensive exposure to the water and environment in San Francisco. Therefore, it is possible that they had a higher risk of being colonized by S. marcescens relative to the general population.
Biologically, implants that are colonized with S. marcescens have the potential to become a potent nidus for infection. In 1996, Chen et al. [8] published an in vitro and in vivo study of S. marcescens in saline, showing that S. marcescens thrives and multiplies exponentially in human saline breast implants for many years. S. marcescens survived in vitro in saline-filled implants and proliferated 80-fold in 7 days, plateauing at the end of 3 weeks. Chemical analyses revealed the presence of glucose in the saline, likely from diffusion across the outer shell of the implant. Chen et al. [8] hypothesized that the survival of S. marcescens was partially dependent on the glucose rich environment. As our patients above likely had environmental exposure to S. marcescens, the Chen et al. [8] study suggests S. marcescens has the potential to proliferate Left breast cavity at the time of tissue expander explant, with orange-red pigmentation of the tissue and expander which is characteristic of Serratia marcescens. If the patients in our report were colonized with S. marcescens while healthy, they were likely at higher risk of infection or hematologic seeding from this bacteria while immunocompromised and postsurgery. Furthermore, at a time of infectious vulnerability, both patients had tissue expanders in place that were susceptible to infection [7] . Extensive literature discusses the virulence of S. marcescens in opportunistic infections. While the first report of opportunistic S. marcescens infection was by Wheat et al. [4] in 1976, over 100 nosocomial outbreaks had been reported by 1977. Common risk factors for S. marcescens infections are invasive instrumentation, extended hospital stay, prolonged antibiotic use, immune compromise, underlying illness, and corticosteroids. The patients in our series had several of the above risk factors, and most importantly were immune compromised at several points of their medical and surgical treatment for breast cancer.
The patients in our report required explantation as a result of their S. marcescens infection. Several recent large scale studies have investigated the relationship between reconstructive implant infection and explantation; however there is no consensus regarding risk factors. McCarthy et al. [9] in 2007 studied 1,170 expander-based reconstructions post mastectomy and found an infection rate of 4.9%. Infection leading to explantation, which occurred in 1.5% of patients, was associated only with smoking, obesity and hypertension. In 2012, Leyngold et al. [10] published a series of 195 women that showed an infection rate of 5%, with inpatient procedures as the only significant risk factor. Reported causative bacteria were E. faecalis, MRSA, and Pseudomonas aeruginosa. Patient geography was not reported in these studies.
National US data shows that S. marcescens is associated with 1.4% of bloodstream infections and 3.5% of nosocomial pneumonia [7] . However, its prevalence in soft tissue infections is not reported locally or nationally. Moreover, given our small sample size and the low incidence of breast infections overall, it is difficult to show statistically significant risk factors for S. marcescens stratified by geography. Nonetheless, close monitoring of patients with geographical risk factors is not burdensome and antibiotic prophylaxis that covers S. marcescens , e.g., quinolones, may be considered perioperatively if the surgeon believes that benefits outweigh the harm of a broader spectrum antibiotic. Also, if signs of infection emerge postoperatively for patients with ties to San Francisco, surgeons could have a lower threshold to treat with antibiotics that cover S. marcescens.
S. marcescens has a complex history in epidemiology and medicine. Postmastectomy tissue expander-based reconstruction patients are a vulnerable group, as they are immunocompromised to various degrees during their operative course. While the link between the San Francisco S. marcescens experiments and opportunistic infection is controversial, several studies have shown that the bacteria has the potential to thrive in the local environment of the city, possibly colonizing the inhabitants. As S. marcescens is a powerful opportunist, these human carriers would likely need to be immunocompromised for colonization to produce adverse effects. A patient's geography is a simple screening tool when considering postoperative risks, especially in the immunocompromised and those receiving prostheses. Closer monitoring for neutropenia during chemotherapy, and a lower threshold to administer S. marcescens targeted antibiotics may be warranted in these patients.
